Oxford-Emergent Tuberculosis Consortium Inks Commercial License ... - Trading Markets (press release) - Oxford-Emergent Tuberculosis Consortium Inks Commercial License ...Trading Markets (press release), CA"We are pleased that the Oxford-Emergent Tuberculosis Consortium was able to enter into this agreement with Vivalis to support the production of MVA85A, the most clinically advanced TB vaccine candidate targeting one of the world's deadliest diseases," ... [Google TB NEWS]